Clopidogrel and omeprazole drug interaction
Pro Research Analysisby 
Searched over 200M research papers
Clopidogrel and Omeprazole Drug Interaction: Mechanisms and Clinical Impact
CYP2C19 Inhibition and Reduced Clopidogrel Efficacy
Clopidogrel is an antiplatelet medication that requires activation by the liver enzyme CYP2C19. Omeprazole, a commonly used proton pump inhibitor (PPI), is a strong inhibitor of CYP2C19. When these drugs are taken together, omeprazole can significantly reduce the formation of clopidogrel’s active metabolite, leading to decreased antiplatelet effects and potentially compromising the intended cardiovascular protection of clopidogrel 1245+1 MORE.
Pharmacodynamic and Pharmacokinetic Evidence
Multiple studies have shown that co-administration of omeprazole with clopidogrel leads to a substantial reduction in the active metabolite of clopidogrel and a measurable decrease in its ability to inhibit platelet aggregation. This effect is not seen with all PPIs; for example, pantoprazole does not significantly impact clopidogrel’s efficacy, suggesting the interaction is specific to certain PPIs like omeprazole 16. Even separating the dosing times or increasing the clopidogrel dose does not fully overcome this interaction .
Clinical Outcomes: Myocardial Infarction and Mortality
Large-scale and retrospective studies indicate that patients taking both clopidogrel and omeprazole may have a higher risk of adverse cardiovascular events, particularly myocardial infarction, compared to those taking clopidogrel alone. However, the risk of all-cause mortality or stroke does not appear to be significantly increased in all populations, though certain subgroups (such as specific ethnicities or those with additional risk factors) may be more vulnerable 78. Some studies also highlight that the negative impact on clinical outcomes may be more pronounced in patients with specific genetic backgrounds affecting CYP2C19 function 378.
Prescribing Trends and Recommendations
Despite warnings from regulatory agencies, the combination of clopidogrel and omeprazole is still frequently prescribed, although its use has declined in recent years as awareness of the interaction has grown. Education for healthcare providers is recommended to further reduce inappropriate co-prescribing, especially since safer alternatives like pantoprazole or ranitidine are available and do not interfere with clopidogrel’s antiplatelet action 3610.
Bidirectional Interaction
There is also evidence that clopidogrel can affect the metabolism of omeprazole, altering the levels of omeprazole and its metabolites. This interaction is more pronounced in individuals who are extensive metabolizers of CYP2C19, further complicating the co-administration of these drugs .
Conclusion
The interaction between clopidogrel and omeprazole is clinically significant, primarily due to omeprazole’s inhibition of CYP2C19, which reduces clopidogrel’s effectiveness in preventing cardiovascular events. This interaction does not extend to all PPIs, with pantoprazole being a safer alternative. Clinicians should avoid prescribing omeprazole with clopidogrel when possible and consider patient-specific factors, including genetic background and alternative medications, to optimize cardiovascular outcomes.
Sources and full results
Most relevant research papers on this topic
Interconnection between injectable omeprazole and clopidogrel tablet: a comprehensive analysis of clinical and pharmacological implications
Injectable omeprazole and clopidogrel tablet may compromise the antiplatelet efficacy of clopidogrel due to potential pharmacokinetic and pharmacodynamic interactions.
Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study
Ranitidine does not influence platelet aggregability response to clopidogrel, unlike omeprazole, which reduces clopidogrel efficacy in stable coronary artery disease patients.
A pharmacokinetic model of drug-drug interaction between clopidogrel and omeprazole at CYP2C19 in humans
Our mathematical model successfully describes the drug-drug interaction between clopidogrel and omeprazole in humans, potentially aiding in predicting plasma levels of clopidogrel and its active metabolite.
DOI